Young adults with ALL benefit from therapies developed for children

(University of Chicago Medical Center) A large, prospective clinical trial adds to mounting evidence that adolescent and young adult patients -- aged 16 to 39 with acute lymphoblastic leukemia -- fare better when treated with high-intensity pediatric protocols than previous patients treated on adult regimens.